NEW YORK, Oct. 11, 2021 (GLOBE NEWSWIRE) — atai Life Sciences (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced the launch of PsyProtix, a new platform company formed with Chymia LLC, a Duke University biotechnology spinout. PsyProtix is a precision psychiatry company focused on developing therapeutics for…


Previous articlePTSF80 – Decriminalization in Seattle, San Pedro, and The Dark Web
Next articlePT266 – Jerry B. Brown, Ph.D. – Psychedelics: Past, Present, and Future